-
Something wrong with this record ?
Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study
L. Štěpánek, M. Nakládalová, A. Boriková, D. Horáková, L. Štěpánek, R. Večeřová, P. Sauer
Language English Country Netherlands
Document type Journal Article
NLK
ProQuest Central
from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest)
from 2002-01-01 to 2 months ago
Family Health Database (ProQuest)
from 2002-01-01 to 2 months ago
Health Management Database (ProQuest)
from 2002-01-01 to 2 months ago
Public Health Database (ProQuest)
from 2002-01-01 to 2 months ago
- MeSH
- COVID-19 * immunology prevention & control epidemiology MeSH
- Adult MeSH
- Immunoglobulin G blood immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mumps prevention & control MeSH
- Antibodies, Viral blood immunology MeSH
- Retrospective Studies MeSH
- SARS-CoV-2 immunology MeSH
- Immunization, Secondary * MeSH
- Measles prevention & control immunology MeSH
- Measles-Mumps-Rubella Vaccine * immunology administration & dosage MeSH
- Rubella prevention & control MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: The potential cross-protective effect of measles, mumps, and rubella (MMR) vaccination against coronavirus disease 2019 (COVID-19) is debated. Although immunological studies suggest cross-reactivity between MMR-induced immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), epidemiological evidence remains inconclusive. This study examined the association between an additional MMR dose and both COVID-19 clinical and serological outcomes in an adult cohort with verified pre-pandemic measles immunity. METHODS: In 2019, prior to the COVID-19 pandemic, 3027 healthcare workers from a Czech university hospital underwent measles serology testing. Seronegative individuals were offered a single additional MMR dose. Between 2020 and 2021, 261 individuals from the original sample subsequently contracted COVID-19 and underwent post-infection SARS-CoV-2 immunoglobulin G (IgG) serology testing, having remained unvaccinated against COVID-19 until that time. RESULTS: Among 212 women and 49 men (mean age: 42.7 years), 150 were measles-seropositive (without additional vaccination) and 111 were measles-seronegative but received an additional MMR dose. Following COVID-19, 216 participants (82.8 %) exhibited SARS-CoV-2 IgG seropositivity. No significant relationship was observed between measles immunity or MMR vaccine administration and COVID-19 clinical characteristics. However, individuals who received an additional MMR dose were significantly more likely to develop SARS-CoV-2 IgG seropositivity (88.3 % vs. 78.7 %; p = 0.042). Regression analysis confirmed additional MMR vaccination as an independent predictor of post-COVID-19 seropositivity (odds ratio 1.81, 95 % confidence interval 1.17-2.81, p = 0.008), irrespective of the interval between MMR vaccination and COVID-19 symptom onset. No correlation was found between pre-pandemic measles antibody titers and SARS-CoV-2 antibody levels (r = 0.09, p = 0.246). CONCLUSION: While no protective effect of adult MMR vaccination on COVID-19 clinical outcomes was observed, a significant immunological interaction was identified. These findings align with the concept of trained immunity and warrant further investigation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015612
- 003
- CZ-PrNML
- 005
- 20250731091126.0
- 007
- ta
- 008
- 250708e20250512ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.vaccine.2025.127232 $2 doi
- 035 __
- $a (PubMed)40359811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Štěpánek, Ladislav $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic; Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic. Electronic address: ladislav.stepanek@upol.cz
- 245 10
- $a Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study / $c L. Štěpánek, M. Nakládalová, A. Boriková, D. Horáková, L. Štěpánek, R. Večeřová, P. Sauer
- 520 9_
- $a BACKGROUND: The potential cross-protective effect of measles, mumps, and rubella (MMR) vaccination against coronavirus disease 2019 (COVID-19) is debated. Although immunological studies suggest cross-reactivity between MMR-induced immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), epidemiological evidence remains inconclusive. This study examined the association between an additional MMR dose and both COVID-19 clinical and serological outcomes in an adult cohort with verified pre-pandemic measles immunity. METHODS: In 2019, prior to the COVID-19 pandemic, 3027 healthcare workers from a Czech university hospital underwent measles serology testing. Seronegative individuals were offered a single additional MMR dose. Between 2020 and 2021, 261 individuals from the original sample subsequently contracted COVID-19 and underwent post-infection SARS-CoV-2 immunoglobulin G (IgG) serology testing, having remained unvaccinated against COVID-19 until that time. RESULTS: Among 212 women and 49 men (mean age: 42.7 years), 150 were measles-seropositive (without additional vaccination) and 111 were measles-seronegative but received an additional MMR dose. Following COVID-19, 216 participants (82.8 %) exhibited SARS-CoV-2 IgG seropositivity. No significant relationship was observed between measles immunity or MMR vaccine administration and COVID-19 clinical characteristics. However, individuals who received an additional MMR dose were significantly more likely to develop SARS-CoV-2 IgG seropositivity (88.3 % vs. 78.7 %; p = 0.042). Regression analysis confirmed additional MMR vaccination as an independent predictor of post-COVID-19 seropositivity (odds ratio 1.81, 95 % confidence interval 1.17-2.81, p = 0.008), irrespective of the interval between MMR vaccination and COVID-19 symptom onset. No correlation was found between pre-pandemic measles antibody titers and SARS-CoV-2 antibody levels (r = 0.09, p = 0.246). CONCLUSION: While no protective effect of adult MMR vaccination on COVID-19 clinical outcomes was observed, a significant immunological interaction was identified. These findings align with the concept of trained immunity and warrant further investigation.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a vakcína proti spalničkám, příušnicím a zarděnkám $x imunologie $x aplikace a dávkování $7 D022542
- 650 12
- $a COVID-19 $x imunologie $x prevence a kontrola $x epidemiologie $7 D000086382
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a protilátky virové $x krev $x imunologie $7 D000914
- 650 12
- $a sekundární imunizace $7 D007117
- 650 _2
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a imunoglobulin G $x krev $x imunologie $7 D007074
- 650 _2
- $a spalničky $x prevence a kontrola $x imunologie $7 D008457
- 650 _2
- $a příušnice $x prevence a kontrola $7 D009107
- 650 _2
- $a zarděnky $x prevence a kontrola $7 D012409
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nakládalová, Marie $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic
- 700 1_
- $a Boriková, Alena $u Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Zdravotníků 248/7, 77900 Olomouc, Czech Republic
- 700 1_
- $a Horáková, Dagmar $u Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
- 700 1_
- $a Štěpánek, Lubomír $u Department of Statistics and Probability, Faculty of Informatics and Statistics, Prague University of Economics and Business, Churchill Square 1938/4, 13067 Prague, Czech Republic
- 700 1_
- $a Večeřová, Renata $u Department of Microbiology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
- 700 1_
- $a Sauer, Pavel $u Department of Microbiology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77900 Olomouc, Czech Republic
- 773 0_
- $w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 57 (20250512), s. 127232
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40359811 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091120 $b ABA008
- 999 __
- $a ok $b bmc $g 2366460 $s 1252737
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 57 $c - $d 127232 $e 20250512 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
- LZP __
- $a Pubmed-20250708